BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

...By Stephen Hansen and Paul Bonanos, Associate Editors FDA approved Ukoniq umbralisib from TG Therapeutics Inc. (NASDAQ:TGTX) to...
...Food and Drug Administration (FDA) Adverum Biotechnologies Inc. Bristol Myers Squibb Co. TG Therapeutics Inc. ViiV Healthcare Ltd. FDA uniQure N.V. Astellas Bristol Myers Squibb Viiv Healthcare Avrobio Adverum TG Therapeutics...
BioCentury | Dec 31, 2020
Distillery Therapeutics

BRD4 as a DMD target

...malignancies and solid tumors.Jubilant Life Sciences Ltd. (NSE:JUBILANT; BSE:530019), Checkpoint Therapeutics Inc. (NASDAQ:CKPT), Fortress Biotech Inc. (NASDAQ:FBIO) and TG Therapeutics Inc....
BioCentury | Aug 15, 2020
Product Development

Aug. 14 Quick Takes: Challenge data for CanSino COVID-19 vaccine; plus Warp Speed-McKesson, BioMarin, TG, Solasia-Isofol

...– Casein kinase 1 epsilon BC Staff Ad5-nCoV vosoritide (BMN 111, bmn-111) umbralisib (TGR-1202, rp5264) CanSino Biologics Inc. McKesson Corp. BioMarin Pharmaceutical Inc. TG Therapeutics Inc. Solasia...
BioCentury | May 15, 2020
Finance

As biotech IPO pace quickens, ADC Therapeutics garners largest postmoney valuation of the year

...term, on the back of substantial inflows into the sector. After market close on Thursday, TG Therapeutics Inc....
BioCentury | May 9, 2020
Management Tracks

O’Connor joins TG Therapeutics as CSO; plus changes at FogPharma, Gemini, Dicerna, Akcea and more

...Cancer and autoimmune company TG Therapeutics Inc. (NASDAQ:TGTX) hired Owen O’Connor as CSO. He was director of the...
...Foerster was senior director of commercial development at Pfizer Inc. (NYSE:PFE) in 2009-12. Robin Sawka, BioCentury Staff TG Therapeutics Inc. FOG...
BioCentury | May 7, 2020
Finance

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

...$13.75, a 6% discount from its Tuesday close of $14.61. RA invests $40M in TG TG Therapeutics Inc....
BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

...TG’s combo meets Phase III leukemia endpoint TG Therapeutics Inc. (NASDAQ:TGTX) climbed $4.23 (34%) to $16.69 on Tuesday...
...Staff vadadustat (MT-6548, akb-6548) ADVM-022 (AAV.7m8-aflibercept) ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib (TGR-1202, rp5264) SRI International Exscientia Ltd. Tolmar Inc. Akebia Therapeutics Inc. Adverum Biotechnologies Inc. TG Therapeutics Inc. Gonadotropin...
BioCentury | Oct 28, 2019
Clinical News

TG makes case for umbralisib as safer lymphoma option

...Bolstering support for what could be the third PI3Kδ inhibitor to gain FDA approval, TG Therapeutics said...
...met the primary endpoint in a second lymphoma indication in the Phase IIb UNITY-NHL trial. TG Therapeutics Inc....
...Targets: PI3Kδ - Phosphoinositide 3-kinase δ; PI3Kγ - Phosphoinositide 3-kinase γ Sandi Wong, Staff Writer umbralisib (TGR-1202, rp5264) TG Therapeutics Inc. Phosphoinositide...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

...IgG2 Fc domain, and induces direct tumor killing via a programmed cell death pathway. 4) TG Therapeutics Inc....
...known as Tioma Therapeutics Inc., Arch raised $86 million in its 2016 series A round. TG Therapeutics Inc....
...Immunotherapeutics S.A. (Euronext:OSE), Nantes, France Stanford University, Stanford, Calif. Surface Oncology Inc. (NASDAQ:SURF), Cambridge, Mass. TG Therapeutics Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:IMV) 3/1/19 $22.4 $210.0 $147.2 -30% Mersana Therapeutics Inc. (NASDAQ:MRSN) 3/1/19 $97.8 $190.7 $193.3 1% TG Therapeutics Inc....
Items per page:
1 - 10 of 129
BioCentury | Feb 9, 2021
Product Development

Feb. 8 Quick Takes: FDA approves TG’s lymphoma therapy; plus uniQure, Astellas, BMS, Viiv, Avrobio and Veru

...By Stephen Hansen and Paul Bonanos, Associate Editors FDA approved Ukoniq umbralisib from TG Therapeutics Inc. (NASDAQ:TGTX) to...
...Food and Drug Administration (FDA) Adverum Biotechnologies Inc. Bristol Myers Squibb Co. TG Therapeutics Inc. ViiV Healthcare Ltd. FDA uniQure N.V. Astellas Bristol Myers Squibb Viiv Healthcare Avrobio Adverum TG Therapeutics...
BioCentury | Dec 31, 2020
Distillery Therapeutics

BRD4 as a DMD target

...malignancies and solid tumors.Jubilant Life Sciences Ltd. (NSE:JUBILANT; BSE:530019), Checkpoint Therapeutics Inc. (NASDAQ:CKPT), Fortress Biotech Inc. (NASDAQ:FBIO) and TG Therapeutics Inc....
BioCentury | Aug 15, 2020
Product Development

Aug. 14 Quick Takes: Challenge data for CanSino COVID-19 vaccine; plus Warp Speed-McKesson, BioMarin, TG, Solasia-Isofol

...– Casein kinase 1 epsilon BC Staff Ad5-nCoV vosoritide (BMN 111, bmn-111) umbralisib (TGR-1202, rp5264) CanSino Biologics Inc. McKesson Corp. BioMarin Pharmaceutical Inc. TG Therapeutics Inc. Solasia...
BioCentury | May 15, 2020
Finance

As biotech IPO pace quickens, ADC Therapeutics garners largest postmoney valuation of the year

...term, on the back of substantial inflows into the sector. After market close on Thursday, TG Therapeutics Inc....
BioCentury | May 9, 2020
Management Tracks

O’Connor joins TG Therapeutics as CSO; plus changes at FogPharma, Gemini, Dicerna, Akcea and more

...Cancer and autoimmune company TG Therapeutics Inc. (NASDAQ:TGTX) hired Owen O’Connor as CSO. He was director of the...
...Foerster was senior director of commercial development at Pfizer Inc. (NYSE:PFE) in 2009-12. Robin Sawka, BioCentury Staff TG Therapeutics Inc. FOG...
BioCentury | May 7, 2020
Finance

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

...$13.75, a 6% discount from its Tuesday close of $14.61. RA invests $40M in TG TG Therapeutics Inc....
BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

...TG’s combo meets Phase III leukemia endpoint TG Therapeutics Inc. (NASDAQ:TGTX) climbed $4.23 (34%) to $16.69 on Tuesday...
...Staff vadadustat (MT-6548, akb-6548) ADVM-022 (AAV.7m8-aflibercept) ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib (TGR-1202, rp5264) SRI International Exscientia Ltd. Tolmar Inc. Akebia Therapeutics Inc. Adverum Biotechnologies Inc. TG Therapeutics Inc. Gonadotropin...
BioCentury | Oct 28, 2019
Clinical News

TG makes case for umbralisib as safer lymphoma option

...Bolstering support for what could be the third PI3Kδ inhibitor to gain FDA approval, TG Therapeutics said...
...met the primary endpoint in a second lymphoma indication in the Phase IIb UNITY-NHL trial. TG Therapeutics Inc....
...Targets: PI3Kδ - Phosphoinositide 3-kinase δ; PI3Kγ - Phosphoinositide 3-kinase γ Sandi Wong, Staff Writer umbralisib (TGR-1202, rp5264) TG Therapeutics Inc. Phosphoinositide...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

...IgG2 Fc domain, and induces direct tumor killing via a programmed cell death pathway. 4) TG Therapeutics Inc....
...known as Tioma Therapeutics Inc., Arch raised $86 million in its 2016 series A round. TG Therapeutics Inc....
...Immunotherapeutics S.A. (Euronext:OSE), Nantes, France Stanford University, Stanford, Calif. Surface Oncology Inc. (NASDAQ:SURF), Cambridge, Mass. TG Therapeutics Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:IMV) 3/1/19 $22.4 $210.0 $147.2 -30% Mersana Therapeutics Inc. (NASDAQ:MRSN) 3/1/19 $97.8 $190.7 $193.3 1% TG Therapeutics Inc....
Items per page:
1 - 10 of 129